{
}
UBS has maintained a 'Buy' rating for Orsted, setting a target price of 520 Danish kroner. Analyst Mark Freshney highlighted concerns over further write-downs and delays in the Sunrise Wind project, which are impacting the company's outlook. Orsted, a leading Danish energy firm, primarily focuses on offshore wind farms, contributing significantly to its revenue.
UBS has maintained its 'Buy' rating for Orsted, setting a target price of 520 Danish crowns. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
UBS has maintained its "Buy" rating for Orsted, setting a target price of 520 Danish kroner. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
Analysts have updated their recommendations for several companies, with notable changes including Accor's price target raised to EUR 54 and Legrand upgraded to buy with a target of EUR 125. UBS Group was downgraded to underperform, while Renault's target increased to EUR 68. Other adjustments include Michelin and Ipsen, both seeing target revisions.
UBS has maintained its "Buy" rating for Orsted, setting a target price of 520 Danish crowns. Analyst Mark Freshney highlighted concerns over further write-offs and delays in the Sunrise Wind project, which are negatively impacting the company's outlook.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight-loss injection, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that rival Eli Lilly's weight loss drug, Zepbound, has seen a stronger recovery in prescriptions compared to Novo's Wegovy following the Christmas period.
UBS has rated Novo Nordisk as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content reflects the views of individual authors rather than wallstreetONLINE.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish kroner. This decision follows positive study results indicating that the high-dose weight loss drug Wegovy leads to greater weight loss compared to lower doses, according to analyst Jo Walton.
Novo Nordisk A/S focuses on the design, manufacture, and marketing of pharmaceutical products, with 92.6% of sales from diabetes and obesity treatments and 7.4% from rare disease therapies. Geographically, 54.9% of sales are in the United States, followed by Europe-Middle East-Africa at 21.9%, and other regions.
DNK
Country
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains buy rating for orsted with target price of 520 kroner
14:06 21.01.2025
ubs upgrades orsted to buy with target price of 520 kroner
09:19 21.01.2025
ubs maintains buy rating for orsted with target price of 520 kroner
09:19 21.01.2025
analysts update recommendations and price targets for major european companies
British Pound Sterling
Danish Krone
Swiss Franc
Euro
Swedish Krona
EXOSENS
Rightmove PLC
Ipsen S.A.
Pluxee N.V.
Accor SA
Legrand SA
Qt Group Oyj
Schneider Electric S.E.
Schindler Holding AG
Compagnie Financière Richemont AG
Fagerhult AB
Icade
Big Yellow Group Plc
AVOLTA N
BT Group plc
Michelin
RENAULT
UBS Group AG
Gecina
Netcompany Group A/S
Covivio
Swedbank AB (publ)
Alstom SA
Ubisoft Entertainment
Capgemini SE
BELIMO Holding AG
Edenred SE
USA
FRA
SWE
CHE
DNK
GBR
Show more
08:38 21.01.2025
ubs upgrades orsted to buy with target price of 520 kroner
08:19 21.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
08:15 21.01.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
08:04 21.01.2025
ubs rates novo nordisk as buy amid investment considerations and risks
17:08 17.01.2025
ubs maintains buy rating for novo nordisk with positive wegovy study results
17:08 17.01.2025
novo nordisk reports strong sales in diabetes and rare disease treatments
16:56 17.01.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Market Analysis and Predictions
CEO Changes
Banking Regulations
Industry Mergers & Acquisitions
Energy Sector Developments
Global Trade Developments
Startups & Entrepreneurship
Government Policies
Financial Scams and Security
Domestic Politics
Supply Chain Management
Hedge Funds & Private Equity
Central Bank Actions
Workplace Trends
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
Apple Inc.
UBS Group AG
Capital One Financial Corporation
NVIDIA Corporation
Bank of America Corporation
The Goldman Sachs Group, Inc.
Morgan Stanley
Commerzbank AG
Amazon.com, Inc.
SpaceXCoin USD
Deutsche Bank RV Global PP
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
Berkshire Hathaway Inc.
Google Inc.
Citigroup Inc.
SAP SE
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Swiss Franc
British Pound Sterling
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
Singapore Dollar
United Arab Emirates Dirham
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Russian Ruble
Ghanaian Cedi
Canadian Dollar
Turkish Lira
People: